Athira Pharma CEO on leave amid altered image claims

fr24news– The chief executive of Athira Pharma, a biotechnology company developing treatments for Alzheimer’s disease and other neurodegenerative diseases, has been placed on temporary leave as her former university investigates allegations that she has published several articles containing images edited while she was a graduate student.

The Seattle-based company did not disclose the reasons for the Leen Kawas investigation, but STAT learned that these were allegations of altered images in four separate articles of which Kawas is the lead author. Western blot images, used to determine the presence of specific proteins in biological samples, appear to have been altered from their original state, according to two imaging experts who spoke with STAT.

Unlock this article by subscribing to STAT + and enjoy your first 30 days free!TO START

Related Articles

Back to top button